Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | ATP4A | P20648 | 3/20 | 0.45 |
| ▸ | ATP4B | P51164 | 3/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072324 | 0.95 | C5AR1 (0.44) | DRD2DRD3ATP4AATP4BC5AR1 | |
| SCHEMBL5136713 | 0.95 | ATP4A (0.46) | DRD2DRD3ATP4AATP4BC5AR1 | |
| SCHEMBL5070125 | 0.93 | L3MBTL1 (0.51) | DRD2DRD3ATP4AATP4BC5AR1 | |
| SCHEMBL5072351 | 0.93 | ATP4A (0.47) | DRD2DRD3ATP4AATP4BC5AR1 | |
| SCHEMBL5135957 | 0.93 | ATP4A (0.45) | DRD2DRD3ATP4AATP4BC5AR1 | |
| SCHEMBL5134960 | 0.93 | ATP4A (0.52) | DRD2DRD3ATP4AATP4B | |
| SCHEMBL5135582 | 0.92 | ATP4A (0.44) | DRD2DRD3ATP4AATP4BC5AR1 | |
| SCHEMBL5135994 | 0.92 | KDM4E (0.48) | DRD2DRD3ATP4AATP4BC5AR1 | |
| SCHEMBL5135687 | 0.92 | C5AR1 (0.45) | DRD2DRD3C5AR1TSHRMAPT | |
| SCHEMBL5137431 | 0.91 | ATP4A (0.50) | DRD2DRD3ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |